Andrew Witty, who recently retired as CEO at drug giant GlaxoSmithKline, is now a partner at Hatteras Venture Partners.
Hatteras announced Witty’s addition early Tuesday.
“We are thrilled to welcome Andrew to Hatteras Venture Partners. He brings unparalleled strategic insights and extensive industry experience to the firm and to our portfolio of emerging companies,” said Bob Ingram, General Partner of Durham-based Hatteras.
“Having had the pleasure of serving as Andrew’s mentor when I was CEO of Glaxo, it is hard to fully express my pride in having him join our dynamic team of company builders.”
Witty has another Triangle connection even though he left GSK earlier this year. He’s also a member of the board at G1 Therapeutics.
Witty will “focus on strategic positioning of Hatteras and its portfolio companies,” Hatteras said in the announcement.
He currently is chancellor of the University of Nottingham in England.
“Joining Hatteras gives me an exciting new opportunity to nurture amazing science for the benefit of patients,” said Witty. “The firm has an outstanding track record of finding novel science in the halls of academia and translating that science into successful companies. I cannot think of a better objective in the evolving health care environment than capitalizing this kind of innovation.”
Hatteras has more than $450 million under management.
Christy Shaffer of Hatteras sits on the G1 board along with Witty.